Table 1.
Efficacy of peptide receptor radionuclide therapy (PRRT) in patients with advanced RR-DTCa
| Reference (Publish Year) | Country | N | Sex | Age (year) | Tumor Classification | Site of metastasis | Prior treatments (Iodine cumulative activity GBq (med)) | Ligand (Radionuclide Chelator Peptide) | Cumulative activity (GBq) | Response criteria | TTP in SD (month) | Follow-Up duration median: (months) | Response |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Czepczynski R et al. (2014) [15] | Poland | 6 | F/M: (9/2) | Median: 65 (4781) | 3FTC, 3HCTC | B/Lu/M | TT/ND/EBR/RIT (3.1) | 90Y-DOTATOC | 3.7_14.8 | Biochemical | NA | 21 (2_68) | 4PD, 1PR, 1SD |
| RECIST | 2PD, 2SD. 1PR | ||||||||||||
| Versari A et al. (2014) [23] | Italy | 11 | F/M | Median: 59 (1978) | 5PTC, 1Oxiphilic, 3FTC, 2Insular | Li/B/Lu | TT/ND/RIT (5.5533.3 (12.95)) | 90Y-DOTATOC | 4.329_17.95 | Biochemical | NA | 7.75 (3.5_11.5) | 11SD |
| RECIST | 2PR, 4SD, 4PD, 1NA | ||||||||||||
| EORTC | 2PR, 5SD, 4PD | ||||||||||||
| Iten F et al. (2009) [24] | Switzerland | 24 | F/M: (12/12) | Median: 58.8 (40.580.6) | 17FTC, 5PTC, 2No specified | NA | TT/ND/RIT | 90Y-DOTATOC | 5.630.3 | Biochemical | NA | 16.8 (1.8_99.1) | 7PR, 17PD |
| Gabriel M et al. (2004) [25] | Austria | 5 | F/M: (2/3) | Median:59 (51_72) | 3FTC, 2PTC | B/Lu/M | TT/ND/RIT (9.25_29.91 (18.87)) | 90Y-DOTATOC | 5.55_7.4 | NA | 5 | NA | 5SD |
| Gorges R et al. (2001) [26] | Germany | 3 | F/M: (2/1) | Median: 68 (51_72) | 1papillary-oxyphilic, 1follicular-oxyphilic, 1Hrthle cell carcinoma | Li/B/Lu/M | TT/ND/EBR/RIT | 90Y-DOTATOC | 1.7_9.62 | Biochemical | NA | 20 (16_31) | 2SD,1PD |
| RECIST | NA | 1SD, 2PD | |||||||||||
| Waldherr C et al. (2001) [27] | Switzerland | 7 | F/M: (4/3) | Median:60 (44_74) | 4PTC, 3FTC | NA | TT/ND/EBR/RIT/C/EN | 90Y-DOTATOC | 1.7_14.8 | WHO | 8 | 15 (1_31) | 2SD, 5PD |
| Virgolini I et al. (2002) [28] | UK | 25 | NA | NA | NA | NA | NA | 90Y-DOTA-Lanerotide | 0 .925_7.06 | WHO | NA | 36 | 3PR, 11SD, 11PD |
| Traub-Weidinger T et al. (2011) [29] | Austria | 4 | NA | Median:66 | 1FTC, 1HCTC | B/Lu | TT/ND/EBR/RIT | 90Y-DOTATOC | 7.2_7.4 | Imaging | NA | (22_27) | 4PD |
| 1FTC, 1PTC | Lu | 90Y-DOTA-Lanerotide | 1.85_3.7 | Imaging | NA | (4_12) | PD | ||||||
| Basu. S et al. (2020) [30] | India | 8 | M/F: (5/3) | 57_83 | 1FTC | B/Lu/M | TT/ND/RIT | 177Lu-DOTATATE | 5.5_25.4 | Biochemical | NA | 34(7_52) | 5PD, 3PR |
| RECIST | 6PD, 2SD | ||||||||||||
| Cinkir, H. Y et al. (2020) [31] | Turkey | 4 | M/F: (3/1) | Median: 64 (49,67) | 1FTC, 3PTC | Lu/B | TT/ND/RIT/C | 177Lu-DOTATATE | 14.8_30.8 | EORTC | 5.5 (1.7_9.4) | 13.8 (4.0_23.7) | 1PD, 2SD, 1PR |
| Roll. W et al. (2018) [32] | Germany | 5 | M/F: (4/1) | Median: 75 (62_89) | 3FTC, 1PTC, 1HCTC | NA | TT/ND/EBR/RIT | 177Lu-DOTATATE | Mean: 7.00.7 | Biochemical | NA | 6 (3_9) | 1FTC PR, 4PD |
| RECIST | 2PD, 2SD, 1PR | ||||||||||||
| EORTC | 3PD, 2SD | ||||||||||||
| Olivn-Sasot. P et al. (2017) [33] | Spain | 1 | F | 69 | FTC | B/Li | TT/ND/C/RIT (10.4) | 177Lu-DOTATATE | 2.6 | Biochemical | NA | 6 | PR |
| Elboa, U et al. (2016) [34] | Turkey | 1 | M | 64 | PTC (tall cell variant) | B/ Lu/M | TT/ND/RIT (27.75) | 177Lu-DOTATATE | 7.4 | Biochemical | NA | After second cycle | PR |
| Jois B et al. (2014) [35] | India | 1 | NA | NA | PTC | Lu | TT/ND/EBR/RIT (NA) | 177Lu-DOTATATE | 7.4 | Biochemical | NA | 3 | PR |
| Imaging | SD | ||||||||||||
| Teunissen JJ et al. (2005) [36] | Netherlands | 5 | F/M | Median: 52 (52_74) | 3HCTC, 1FTC, 1PTC | B/Lu | TT/ND/EBR/C/RIT (1.9_16.7 (12.9)) | 177Lu-DOTATATE | 22.430.1 | Biochemical | Median: 22(4_43) | (4_48) | 2PD, 3PR |
| WHO | 2SD, 1PD, 1PR, 1MRe | ||||||||||||
| Parihar AS et al. (2018) [37] | India | 1 | F | 54 | PTC | B/Lu | TT/ND/RIT (18.5) | 177Lu-DOTA-RGD2 | 5.5 | RECIST | NA | 4 | SD |
| Campenni A et al. (2015) [38] | Italy | 1 | M | 70 | PTC | Lu | TT/ND/RIT (3.7) | 177Lu-DOTATOC | 7.77 | Biochemical | 5 | 5 | PR |
| RECIST | SD | ||||||||||||
| Valkema R et al. (2002) [39] | Netherlands | 5 | NA | Median:70.8 (57.3_76.1) | 4PTC, 1FTC | Lu | TT/ND/BT/RIT | 1111n-Octerotide | 29.51_83.2 | Biochemical | NA | 15.8 (15_16.6) | 1SD, 1PD, 1PR, 2NA |
| SWOG | 15.8 (13.2_28.2) | 1SD, 4PD | |||||||||||
| Krenning E et al. (1999) [40] | Netherlands | 1 | NA | NA | PTC | NA | NA | 1111n-Octerotide | 20_75 | imaging | NA | 24 | 1SD |
| Stokkel MP et al. (2004) [41] | Netherlands | 11 | F/M: (7/4) | Median:67 (4469) | 6PTC, 5FTC | Li/B/Lu/M | TT/ND/EBR/C/Emb/RIT | 111In-DTPA-Octreotide | 14.3_33.1 | Biochemical | NA | 12 (1_12) | 7SD, 3PD, 1NA |
| Imaging | 4SD, 5PD, 2NA | ||||||||||||
| Budiawan H et al. (2013) [6] | Germany | 7 | F/M: (5/2) | Median: 64.5 (26_77) | 4FTC,3HCTC | A/Li/Lu/B | TT/ND/EBR/C/RIT/LITT/REDIFF | 90Y-DOTATATE and 177Lu-DOTATATE | NA | EORTC | NA | 50.4 (34.866) | 1SD, 5PD, 1PR |
| Scalorbi F et al. (2017) [42] | Italy | 21 | F/M: (13/8) | NA | NA | NA | TT/ND/RIT | NA | NA | EORTC | NA | NA | 2PR, 9PD, 10SD |
aAbbreviations: NA Not Available, FTC Follicular Thyroid Carcinoma, RR-DTC Radioiodine-Refractory Differentiated Thyroid Cancer, PTC Papillary Thyroid Carcinoma, HCTC Hurtle Cell Thyroid Carcinoma, TTP Time To Progression
Metastatic Site: A Adrenal, Li Liver, Lu Lung, B Bone, M Mediastinum
Prior treatments: TT Total Thyroidectomy, ND Node Dissection, EBR External Beam Radiation, C Chemotherapy, I Radioactive Iodine therapy, BT Biotherapy with octreotide, LITT Laser- induced thermotherapy, REDIFF Redifferentiation Using Roaccutane
Response: CR Complete Response, PR Partial Remission, SD Stable Disease, PD Progressive Disease, MR Minor Remission